NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis $1.00 -0.02 (-1.96%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.99▼$1.0350-Day Range$0.90▼$1.1752-Week Range$0.82▼$1.90Volume68,828 shsAverage Volume374,094 shsMarket Capitalization$73.32 millionP/E Ratio25.00Dividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get Protalix BioTherapeutics alerts: Email Address Protalix BioTherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside900.0% Upside$10.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth933.33%From $0.06 to $0.62 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector352nd out of 910 stocksBiological Products, Except Diagnostic Industry52nd out of 155 stocks 3.5 Analyst's Opinion Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtalix BioTherapeutics has received no research coverage in the past 90 days.Read more about Protalix BioTherapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PLX. Previous Next 0.0 Dividend Strength Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PLX. Previous Next 1.8 News and Social Media Coverage News SentimentProtalix BioTherapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Protalix BioTherapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.97% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.53% of the stock of Protalix BioTherapeutics is held by institutions.Read more about Protalix BioTherapeutics' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 933.33% in the coming year, from $0.06 to $0.62 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is 25.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is 25.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Protalix BioTherapeutics Stock (NYSE:PLX)Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Read More PLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLX Stock News HeadlinesSeptember 4 at 7:06 AM | tmcnet.comProtalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comProtalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory NotesSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 30, 2024 | msn.comIs Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts?August 28, 2024 | money.usnews.comProtalix BioTherapeutics Inc.August 28, 2024 | americanbankingnews.comEquities Analysts Issue Forecasts for Protalix BioTherapeutics, Inc.'s FY2024 Earnings (NYSE:PLX)August 22, 2024 | finance.yahoo.comPLX: A Focus on Renal Rare DiseaseAugust 17, 2024 | finance.yahoo.comPLX Sep 2024 7.500 call (PLX240920C00007500)September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 14, 2024 | finanznachrichten.deProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business ResultsAugust 14, 2024 | seekingalpha.comProtalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | prnewswire.comProtalix BioTherapeutics Reports Second Quarter 2024 Financial and Business ResultsAugust 13, 2024 | markets.businessinsider.comWhat Wall Street expects from Protalix BioTherapeutics's earningsJuly 28, 2024 | finance.yahoo.comPLX Aug 2024 0.500 put (PLX240816P00000500)June 13, 2024 | prnewswire.comProtalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled GoutMay 29, 2024 | prnewswire.comProtalix BioTherapeutics to Present at the 2024 BIO International ConventionMay 15, 2024 | finance.yahoo.comPLX: First Quarter UpdateMay 13, 2024 | finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...See More Headlines Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:PLX CUSIPN/A CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+900.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio25.00 Forward P/E Ratio16.67 P/E GrowthN/ANet Income$8.31 million Net Margins-38.62% Pretax Margin-39.81% Return on Equity-45.15% Return on Assets-16.63% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio0.98 Sales & Book Value Annual Sales$38.05 million Price / Sales1.93 Cash Flow$0.14 per share Price / Cash Flow6.92 Book Value$0.47 per share Price / Book2.13Miscellaneous Outstanding Shares73,316,000Free Float69,672,000Market Cap$73.32 million OptionableOptionable Beta0.70 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Dror Bashan (Age 57)President, CEO & Director Comp: $1.38MMr. Eyal Rubin M.B.A. (Age 48)Senior VP, CFO, Treasurer & Corporate Secretary Comp: $686.78kMr. Yaron Naos (Age 60)Senior Vice President of Operations Comp: $513.82kMs. Yael FellousVice President of Human ResourcesKey CompetitorsPoseida TherapeuticsNASDAQ:PSTXBiomea FusionNASDAQ:BMEADesign TherapeuticsNASDAQ:DSGNHeron TherapeuticsNASDAQ:HRTXuniQureNASDAQ:QUREView All CompetitorsInsiders & InstitutionsPoint72 Asia Singapore Pte. Ltd.Bought 68,163 shares on 8/15/2024Ownership: 0.093%AQR Capital Management LLCBought 57,106 shares on 8/15/2024Ownership: 0.078%Squarepoint Ops LLCBought 119,949 shares on 8/14/2024Ownership: 0.188%Cubist Systematic Strategies LLCBought 32,031 shares on 8/14/2024Ownership: 0.044%Renaissance Technologies LLCSold 20,100 shares on 8/9/2024Ownership: 1.097%View All Insider TransactionsView All Institutional Transactions PLX Stock Analysis - Frequently Asked Questions How have PLX shares performed this year? Protalix BioTherapeutics' stock was trading at $1.78 at the beginning of 2024. Since then, PLX stock has decreased by 43.8% and is now trading at $1.00. View the best growth stocks for 2024 here. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) posted its earnings results on Wednesday, August, 14th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.05. The business earned $13.47 million during the quarter, compared to analyst estimates of $12.50 million. Protalix BioTherapeutics had a negative trailing twelve-month return on equity of 45.15% and a negative net margin of 38.62%. When did Protalix BioTherapeutics' stock split? Shares of Protalix BioTherapeutics reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Protalix BioTherapeutics' major shareholders? Top institutional investors of Protalix BioTherapeutics include Renaissance Technologies LLC (1.10%), Squarepoint Ops LLC (0.19%), Point72 Asia Singapore Pte. Ltd. (0.09%) and Ground Swell Capital LLC (0.08%). Insiders that own company stock include Aharon Schwartz and Dror Bashan. View institutional ownership trends. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:PLX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.